Aura Biosciences Investor Relations Material

Aura Biosciences Inc. is a biotechnology company focused on developing therapies for cancer treatment. It specializes in the creation of virus-like drug conjugates (VDC) technology, aiming to address tumors with significant unmet medical needs in ocular and urologic oncology. A key development in their portfolio is AU-011, a VDC candidate targeting primary choroidal melanoma. The company also explores the potential of AU-011 for other ocular oncology indications, including choroidal metastases, and is conducting Phase 2 dose-escalation trials. Aura Biosciences is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.